clinical trial · NCT05282108
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaCarcemiaGlivec
brief summary
The purpose of this study is to evaluate Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
started
Jul 20, 2022
primary completion
Aug 1, 2026
completion
Nov 1, 2026
last updated
Mar 26, 2025
detailed description
This is an observational, prospective, cohort study design, where no visits or intervention(s) additional to the daily practice will be performed. In the study site, two cohorts will be identified among eligible patients, followed up, and assessed for a total of 12 months.
official title
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia; a Multicenter, Observational Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol